CALIBER: a phase II randomized feasibility trial of chemoablation with mitomycin‐C vs surgical management in low‐risk non‐muscle‐invasive bladder cancer

Objectives To evaluate the activity of intravesical mitomycin‐C (MMC) to ablate recurrent low‐risk non‐muscle‐invasive bladder cancer (NMIBC) and assess whether it may enable patients to avoid surgical intervention for treatment of recurrence. Patients and Methods CALIBER is a phase II feasibility s...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	BJU international 2020-06, Vol.125 (6), p.817-826
Hauptverfasser:	Mostafid, A. Hugh, Porta, Nuria, Cresswell, Joanne, Griffiths, Thomas R.L., Kelly, John D., Penegar, Steven R., Davenport, Kim, McGrath, John S., Campain, Nicholas, Cooke, Peter, Masood, Shikohe, Knowles, Margaret A., Feber, Andrew, Knight, Allen, Catto, James W.F., Lewis, Rebecca, Hall, Emma
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Intravesical Aged Aged, 80 and over Antibiotics, Antineoplastic - administration & dosage Antibiotics, Antineoplastic - therapeutic use Bladder cancer BladderCancer blcsm chemoablation Chemotherapy Disease management Feasibility Studies Female Humans Invasiveness Male Middle Aged Mitomycin - administration & dosage Mitomycin - therapeutic use Mitomycin C non‐muscle‐invasive bladder cancer Patients Quality of Life randomized trial Surgery Trial Urinary Bladder Neoplasms - drug therapy Urinary Bladder Neoplasms - mortality Urinary Bladder Neoplasms - pathology Urinary Bladder Neoplasms - surgery
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!